Agenda/Scientific Program

The NEW 2025 Symposium on mRNA will bring together industry, academia, and regulatory agencies from around the world to explore how mRNA has become a new modality, how mRNA vaccines are applied against a wide array of infectious diseases, and how many are exploring the application of mRNA agents for other diseases. Speaker presentations, panel discussions, and networking opportunities will give you the opportunity to engage with fellow attendees in meaningful discussions. We look forward to an informative Symposium and hope to see you there. Be ready to network, collaborate, and expand your knowledge.

The full scientific program will be available soon.

CASSS /AMM Joint mRNA Symposium on mRNA Therapy Products 2025

Continued innovation is fueling the expansion and clinical translation of mRNA-based therapies in applications far beyond their use as prophylactic vaccines for COVID-19. The first CASSS Symposium on mRNA explores the expanding landscape of mRNA vaccines and therapeutics, with a focus on manufacturing, quality, and regulatory considerations for this rapidly evolving field.

The Symposium will convene leading global regulators, industry experts, and other key stakeholders to:

• Examine current challenges in the manufacturing, quality, and regulatory arenas.
• Highlight the latest advancements and innovative developments in the field, and.
• Identify opportunities and concrete strategies to support and shape the continued development, expansion, and regulatory approval of mRNA-based products.

Session Topics:

1. Enabling the True Potential of mRNA: This session will explore the evolving landscape of mRNA therapeutics, from innovative modalities to new clinical applications, including personalized neoantigen immunotherapies, gene editors, and protein replacement therapies.
2. Manufacturing Challenges & Innovations: Examines specific challenges of the mRNA manufacturing process and discusses the latest developments and advancements in process optimization.
3. Quality Control, Analytics & Assay Development: Focuses on the QTPP, CQAs, and control strategy for early and late-phase development of mRNA vaccines and therapeutics, including approaches for evaluating potency and comparability.
4. Regulatory Considerations: Leading regulators will discuss their perspectives, ongoing initiatives, and guidelines for mRNA therapies. Industry experts will share key learnings gained from the development and registration of mRNA-based products.

Presentations will be complemented by panel discussions to further explore these issues.